Back to search results

Measuring Environmental Tobacco and Cannabis: Pollutants and Exposures

This study is looking at how exposure to secondhand cannabis smoke affects healthy nonsmokers. Researchers will take healthy adults to public places where cannabis is being used and measure the levels of cannabis byproducts (cannabinoid metabolites) in their urine. The goal is to understand how much of these substances people take in from real-world cannabis smoke exposure. You might be able to join if you are a healthy nonsmoker between 21 and 50 years old, have normal blood pressure and BMI, can exercise moderately, and are not regularly exposed to tobacco or cannabis smoke. The study is currently not recruiting, as its status is unclear.

Study design
This is an unblinded pilot study, meaning participants and researchers will know about the exposure. It plans to enroll 200 healthy nonsmokers.
What's involved
You would be exposed to secondhand cannabis emissions in public places. Researchers will collect urine samples at the start and the morning after exposure, up to 22 hours later.
Compensation
Not stated in the trial record.
Follow-up
Your urine will be tested at baseline (before exposure) and the morning after exposure, up to 22 hours later.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06030674

Measuring Environmental Tobacco and Cannabis: Pollutants and Exposures

Recruiting
NAAges 21–50InterventionalBasic science
University of California, San Francisco
~200 participants
Updated 2026-06-16 on ClinicalTrials.gov
What's tested:Secondhand cannabis emissions/smoke exposure

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in the concentration of urinary cannabinoid metabolites in health nonsmokers exposed to cannabis smoke and emissions
Measured over Baseline (before exposure) and the morning after exposure, up to 22 hours.

Conditions

Healthy

Explore related trials

Healthy

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Suzaynn F Schick · PRINCIPAL_INVESTIGATOR · University of California, San Francisco

Who to contact

Suzaynn F Schick, Phd
[email protected]
4155143535
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Are healthy on the basis of medical history
Have systolic blood pressure \<150
Have diastolic blood pressure \<100
Have BMI between 18.1 and 34.9
Able to perform moderate exercise,
Are not exposed to tobacco or cannabis SHS in their daily lives. (Nonsmoking status and low SHS exposure are determined by self-report on the screening questionnaire, salivary cotinine \< 10 ng/ml and THC \< 50 ng/m and exhaled CO2 below 4 ppm)

Exclusion

Current use of cannabis products, including CBD and edible THC products
Regular exposure to secondhand tobacco or cannabis smoke
Positive SARS-CoV-2 antibody test
Age 18 \< or \> 50
Physician diagnosis of asthma, heart disease, hypertension, thyroid disease, diabetes, renal or liver impairment or glaucoma.
Unstable psychiatric condition (such as current major depression, history of schizophrenia or bipolar disorder) or current use of more than two psychiatric medications
Systolic blood pressure \> 150
Diastolic blood pressure \> 100
Pregnancy or breastfeeding (by urine hCG and/or history)
Alcohol or illicit drug dependence within the past 5 years
BMI \> 35 and \< 18
Current illicit drug use (by history or urine test)
More than 1 pack year smoking history
Ever a daily marijuana smoker
Smoked anything within the last 2 months
Occupational exposure to smoke, dusts OR fumes
Concurrent participation in another clinical trial
Unable to communicate in English
No social security number

What this trial measures

  • Change in the concentration of urinary cannabinoid metabolites in health nonsmokers exposed to cannabis smoke and emissionsBaseline (before exposure) and the morning after exposure, up to 22 hours.

    The concentration of 11-Nor-9-carboxy-THC will be measured in urine with LC/MS-MS. The LOQ for this assay is 15 pg/ml. Anticipated changes in concentration are from BLOQ to 0.5-20 ng/ml. The duration of the exposures will depend on the event or venue at which exposures occur, ranging from 30 minutes to 4 hours. The investigators will compare the concentration of 11-Nor-9-carboxy-THC in participants' urine before exposure to concentrations in the first void of the morning after the day of exposure.